<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="gioacchino.tedeschi@unicampania.it 15 Russo Antonio dottor.russo@gmail.com 15 collab: The Italian chronic" exact="migraine" post="group [1], [2], 0000000417581884 grid.18887.3e Headache and Pain Unit,"/>
 <result pre="license, and indicate if changes were made. Abstract Background Chronic" exact="migraine" post="is a disabling condition that is currently underdiagnosed and"/>
 <result pre="In this narrative review, we discuss the future of chronic" exact="migraine" post="management in relation to recent progress in evidence-based pharmacological"/>
 <result pre="recent progress in evidence-based pharmacological treatment. Findings Patients with chronic" exact="migraine" post="require prophylactic therapy to reduce the frequency of migraine"/>
 <result pre="chronic migraine require prophylactic therapy to reduce the frequency of" exact="migraine" post="attacks, but the only currently available evidence-based prophylactic treatment"/>
 <result pre="the only currently available evidence-based prophylactic treatment options for chronic" exact="migraine" post="are topiramate and onabotulinumtoxinA. Improved prophylactic therapy is needed"/>
 <result pre="therapy is needed to reduce the high burden of chronic" exact="migraine" post="in Italy. Monoclonal antibodies that target the calcitonin gene-related"/>
 <result pre="antibodies that target the calcitonin gene-related peptide (CGRP) pathway of" exact="migraine" post="pathogenesis have been specifically developed for the prophylactic treatment"/>
 <result pre="not benefitting from their current treatment. Conclusions Treatment of chronic" exact="migraine" post="is a dynamic and rapidly advancing area of research."/>
 <result pre="personal, social and economic burden of chronic migraine. Keywords Chronic" exact="migraine" post="Fremanezumab onabotulinumtoxinA Prophylaxis Topiramate Anti-CGRP monoclonal antibodies Background Chronic"/>
 <result pre="migraine Fremanezumab onabotulinumtoxinA Prophylaxis Topiramate Anti-CGRP monoclonal antibodies Background Chronic" exact="migraine" post="(CM), defined by the current International Headache Society classification"/>
 <result pre="as headache occurring on ≥15 days/month for &amp;gt; 3 months with features of" exact="migraine" post="on ≥8 days/month [ 1], is a disabling condition that"/>
 <result pre="frequency, especially if they have psychiatric comorbidities. Compared with episodic" exact="migraine" post="(EM), CM is less common but is associated with"/>
 <result pre="progression include the frequency of headache attacks, overuse of acute" exact="migraine" post="medication, ineffective acute treatment, stressful life events and obesity"/>
 <result pre="acute migraine medication, ineffective acute treatment, stressful life events and" exact="obesity" post="[ 8, 12, 16, 17]. Medication-overuse headache (MOH) is"/>
 <result pre="is now considered a sequela rather than a cause of" exact="migraine" post="and can co-exist with CM [ 1, 18, 19]."/>
 <result pre="authors’ knowledge of the area. Understanding the pathophysiology of chronic" exact="migraine" post="The pathophysiology of CM is not fully understood, but"/>
 <result pre="modulatory activity [ 21– 23]. It is postulated that recurring" exact="migraine" post="episodes and comorbid conditions, such as medication overuse or"/>
 <result pre="activation of the trigeminovascular pathway, both of which occur in" exact="migraine" post="[ 25, 26], implicate hyperexcitability of certain central nervous"/>
 <result pre="CGRP in headache pain notwithstanding, the first step of the" exact="migraine" post="attack is likely to involve central mechanisms, as suggested"/>
 <result pre="attack stages [ 28], as well as the concept that" exact="migraine" post="may occur without pain in the paediatric population (migraine-associated"/>
 <result pre="paediatric population (migraine-associated periodic syndromes) and in patients who experience" exact="migraine" post="with aura. CGRP, which is involved in pain modulation,"/>
 <result pre="seems to have a major role in the pathogenesis of" exact="migraine" post="{Goldberg, 2015 #47;Ho, 2010 #21;Edvinsson, 2019 #139}. Activation of"/>
 <result pre="cortical spreading depression, which is a key pathophysiological component of" exact="migraine" post="with aura [ 32, 33]. Release of CGRP from"/>
 <result pre="trigeminal nervous system in CM [ 35]. Treatment of chronic" exact="migraine" post="Some patients with low frequency EM can be managed"/>
 <result pre="acute therapy (i.e. drugs taken during the prodrome or the" exact="migraine" post="attack to abort it) without prophylactic treatment, but patients"/>
 <result pre="Whereas the goal of acute therapy is to abort a" exact="migraine" post="attack once it has started, the goals of prophylactic"/>
 <result pre="developing MOH [ 8, 20, 31]. Effective acute treatment of" exact="migraine" post="attacks with triptans may help to prevent progression from"/>
 <result pre="CM, but rather than relying on taking drugs to stop" exact="migraine" post="attacks after they have started, the aim of treatment"/>
 <result pre="aim of treatment for CM should be the prevention of" exact="migraine" post="attacks [ 35]. Fig. 1 Mechanisms of action of"/>
 <result pre="1 Mechanisms of action of antimigraine treatments used in chronic" exact="migraine" post="and emerging treatments in relation to calcitonin gene-related peptide"/>
 <result pre="not responded adequately or are intolerant of commonly prescribed oral" exact="migraine" post="treatments [ 47]. Treatment should be repeated every 3 months."/>
 <result pre="to prevent the development of cortical spreading depression associated with" exact="migraine" post="by modulating ion channels (e.g. blockade of voltage-gated sodium"/>
 <result pre="of principle that targeting the CGRP pathway may effectively prevent" exact="migraine" post="[ 27, 60]. Telcagepant has been investigated for the"/>
 <result pre="CGRP receptor antagonists are currently in phase III development for" exact="migraine" post="(atogepant, rimegepant, and ubrogepant), with atogepant and rimegepant being"/>
 <result pre="excessive CGRP released in the trigeminal sensory nerve fibres during" exact="migraine" post="attacks (Fig. 1) [ 27, 60, 63]. Three anti-CGRP/R"/>
 <result pre="resulted in significant reductions in the primary endpoints of monthly" exact="migraine" post="days and headache hours, respectively, versus placebo [ 63,"/>
 <result pre="significantly reducing both the average number of headache days/month and" exact="migraine" post="days/month compared with placebo in the 12-week period after"/>
 <result pre="Medicines Agency for the prophylactic treatment of chronic and episodic" exact="migraine" post="[ 75, 76] . This review will be based"/>
 <result pre="phase III studies in these indications [ 73, 77]. Chronic" exact="migraine" post="management in Italy On the basis of the results"/>
 <result pre="of therapy would require careful assessment of clinical characteristics of" exact="migraine" post="in each CM patient, as well as their overall"/>
 <result pre="on variables such as lifestyle, behavioral and socio-demographic factors, comorbidities," exact="migraine" post="features before and after chronification (e.g. disease duration; location,"/>
 <result pre="to focus attention on preventive rather than acute treatment of" exact="migraine" post="attacks in patients with CM. To this end, neurologists,"/>
 <result pre="by a combined treatment approach of acute treatment to reduce" exact="migraine" post="severity and prophylactic treatments to reduce migraine frequency ["/>
 <result pre="treatment to reduce migraine severity and prophylactic treatments to reduce" exact="migraine" post="frequency [ 11]. A pooled analysis of clinical trial"/>
 <result pre="with topiramate in patients with EM may help to prevent" exact="migraine" post="chronification [ 88]. Anti-CGRP monoclonal antibodies may also prove"/>
 <result pre="a phase II clinical trial in which fremanezumab significantly reduced" exact="migraine" post="days versus placebo in patients with high-frequency migraine ["/>
 <result pre="significantly reduced migraine days versus placebo in patients with high-frequency" exact="migraine" post="[ 72]. Although in this review we focus on"/>
 <result pre="mechanism of action of these treatments is so specific to" exact="migraine" post="that inappropriate use will almost invariably result in treatment"/>
 <result pre="this devastating disease. Abbreviations CGRP Calcitonin gene-related peptide CM Chronic" exact="migraine" post="EM Episodic migraine ICHD-3 International Headache Society classification of"/>
 <result pre="Abbreviations CGRP Calcitonin gene-related peptide CM Chronic migraine EM Episodic" exact="migraine" post="ICHD-3 International Headache Society classification of Headache Disorders MOH"/>
 <result pre="contributions The Authors were the members of The Italian chronic" exact="migraine" post="group. They contributed equally to this work drafting the"/>
 <result pre="2. Bigal ME Serrano D Reed M Lipton RB Chronic" exact="migraine" post="in the population burden, diagnosis, and satisfaction with treatment"/>
 <result pre="Rapoport AM Lipton RB Tepper SJ Sheftell FD Assessment of" exact="migraine" post="disability using the migraine disability assessment (MIDAS) questionnaire: a"/>
 <result pre="Tepper SJ Sheftell FD Assessment of migraine disability using the" exact="migraine" post="disability assessment (MIDAS) questionnaire: a comparison of chronic migraine"/>
 <result pre="the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic" exact="migraine" post="with episodic migraine Headache. 2003 43 4 336 342"/>
 <result pre="assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic" exact="migraine" post="Headache. 2003 43 4 336 342 10.1046/j.1526-4610.2003.03068.x 12656704 6."/>
 <result pre="Turkel C Lipton R Sociodemographic and comorbidity profiles of chronic" exact="migraine" post="and episodic migraine sufferers J Neurol Neurosurg Psychiatry 2010"/>
 <result pre="R Sociodemographic and comorbidity profiles of chronic migraine and episodic" exact="migraine" post="sufferers J Neurol Neurosurg Psychiatry 2010 81 4 428"/>
 <result pre="Young WB Quality-of-life differences between patients with episodic and transformed" exact="migraine" post="Headache. 2001 41 6 573 578 10.1046/j.1526-4610.2001.041006573.x 11437893 8."/>
 <result pre="10.1046/j.1526-4610.2001.041006573.x 11437893 8. Lipton RB Silberstein SD Episodic and chronic" exact="migraine" post="headache: breaking down barriers to optimal treatment and prevention"/>
 <result pre="E De Simone R et al. Underdiagnosis and undertreatment of" exact="migraine" post="in Italy: a survey of patients attending for the"/>
 <result pre="Herberhold J Steiner TJ Poor medical care for people with" exact="migraine" post="in Europe - evidence from the Eurolight study J"/>
 <result pre="D Buse D Scher A Stewart WF Lipton RB Acute" exact="migraine" post="medications and evolution from episodic to chronic migraine: a"/>
 <result pre="WBF Adams AM et al. Fluctuations in episodic and chronic" exact="migraine" post="status over the course of 1 year: implications for"/>
 <result pre="Sungur MA Selekler M Siva A Phenotypic features of chronic" exact="migraine" post="J Headache Pain. 2016 17 26 10.1186/s10194-016-0616-y 26975363 16."/>
 <result pre="26975363 16. Bigal ME Lipton RB Modifiable risk factors for" exact="migraine" post="progression Headache. 2006 46 9 1334 1343 10.1111/j.1526-4610.2006.00577.x 17040331"/>
 <result pre="DC Manack AN Lipton RB Defining the differences between episodic" exact="migraine" post="and chronic migraine Curr Pain Headache Rep 2012 16"/>
 <result pre="Lipton RB Defining the differences between episodic migraine and chronic" exact="migraine" post="Curr Pain Headache Rep 2012 16 1 86 92"/>
 <result pre="C Rapoport AM Update on the pharmacological treatment of chronic" exact="migraine" post="Curr Pain Headache Rep 2016 20 1 6 10.1007/s11916-015-0533-9"/>
 <result pre="1 6 10.1007/s11916-015-0533-9 26728188 21. Mathew NT Pathophysiology of chronic" exact="migraine" post="and mode of action of preventive medications Headache. 2011"/>
 <result pre="D Goor-Aryeh I Ransil BJ Bajwa ZH An association between" exact="migraine" post="and cutaneous allodynia Ann Neurol 2000 47 5 614"/>
 <result pre="Goldberg SW Silberstein SD Targeting CGRP: a new era for" exact="migraine" post="treatment CNS Drugs 2015 29 6 443 452 10.1007/s40263-015-0253-z"/>
 <result pre="443 452 10.1007/s40263-015-0253-z 26138383 28. Schulte LH May A The" exact="migraine" post="generator revisited: continuous scanning of the migraine cycle over"/>
 <result pre="May A The migraine generator revisited: continuous scanning of the" exact="migraine" post="cycle over 30 days and three spontaneous attacks Brain"/>
 <result pre="Lupi C Geppetti P TRPA1 and other TRP channels in" exact="migraine" post="J Headache Pain. 2013 14 1 71 10.1186/1129-2377-14-71 23941062"/>
 <result pre="Fusi C Trevisan G Geppetti P The TRPA1 channel in" exact="migraine" post="mechanism and treatment Br J Pharmacol 2014 171 10"/>
 <result pre="MH Dodick DW Porreca F Targeting TRP channels for novel" exact="migraine" post="therapeutics ACS Chem Neurosci 2014 5 11 1085 1096"/>
 <result pre="CGRP levels in peripheral blood as a biomarker for chronic" exact="migraine" post="Neurology. 2013 81 14 1191 1196 10.1212/WNL.0b013e3182a6cb72 23975872 35."/>
 <result pre="27389092 36. Weatherall MW The diagnosis and treatment of chronic" exact="migraine" post="Ther Adv Chronic Dis 2015 6 3 115 123"/>
 <result pre="Goadsby PJ CGRP and its receptors provide new insights into" exact="migraine" post="pathophysiology Nat Rev Neurol 2010 6 10 573 582"/>
 <result pre="(nVNS) for preventive and acute treatment of episodic and chronic" exact="migraine" post="and migraine-associated sleep disturbance: a prospective observational cohort study"/>
 <result pre="J Eren O Blum B Ruscheweyh R Treatment of chronic" exact="migraine" post="with transcutaneous stimulation of the auricular branch of the"/>
 <result pre="Cho SJ Song TJ Chu MK Treatment update of chronic" exact="migraine" post="Curr Pain Headache Rep 2017 21 6 26 10.1007/s11916-017-0628-6"/>
 <result pre="44. Hepp Z Bloudek LM Varon SF Systematic review of" exact="migraine" post="prophylaxis adherence and persistence J Manag Care Pharm 2014"/>
 <result pre="EB Adherence to oral migraine-preventive medications among patients with chronic" exact="migraine" post="Cephalalgia. 2015 35 6 478 488 10.1177/0333102414547138 25164920 46."/>
 <result pre="Silberstein S OnabotulinumtoxinA: a review in the prevention of chronic" exact="migraine" post="Drugs. 2018 78 5 589 600 10.1007/s40265-018-0894-6 29532439 47."/>
 <result pre="Geppetti P et al. Optimizing the long-term management of chronic" exact="migraine" post="with onabotulinumtoxinA in real life Expert Rev Neurother 2018"/>
 <result pre="and divalproex sodium for prophylactic treatment of episodic or chronic" exact="migraine" post="Headache. 2008 48 2 210 220 10.1111/j.1526-4610.2007.00949.x 18047502 51."/>
 <result pre="type a versus amitriptyline for the treatment of chronic daily" exact="migraine" post="Clin Neurol Neurosurg 2010 112 6 463 466 10.1016/j.clineuro.2010.02.004"/>
 <result pre="LA et al. Onabotulinumtoxin a for the management of chronic" exact="migraine" post="in current clinical practice: results of a survey of"/>
 <result pre="T Papetti L Rubio-Beltran E et al. Blocking CGRP in" exact="migraine" post="patients - a review of pros and cons J"/>
 <result pre="Reuter U CGRP monoclonal antibodies for the preventative treatment of" exact="migraine" post="Curr Pain Headache Rep 2018 22 5 38 10.1007/s11916-018-0686-4"/>
 <result pre="Salvatore CA Kane SA CGRP receptor antagonists: toward a novel" exact="migraine" post="therapy Curr Pharm Biotechnol 2011 12 10 1671 1680"/>
 <result pre="AR Goadsby PJ Anti-CGRP monoclonal antibodies: the next era of" exact="migraine" post="prevention? Curr Treat Options Neurol 2017 19 8 27"/>
 <result pre="Randomized controlled trial of the CGRP receptor antagonist telcagepant for" exact="migraine" post="prevention Neurology. 2014 83 11 958 966 10.1212/WNL.0000000000000771 25107879"/>
 <result pre="al. Rimegepant, an oral calcitonin gene–related peptide receptor antagonist, for" exact="migraine" post="N Engl J Med 2019 381 142 149 10.1056/NEJMoa1811090"/>
 <result pre="receptor antagonists and antibodies against CGRP and its receptor in" exact="migraine" post="treatment Br J Clin Pharmacol 2015 80 2 193"/>
 <result pre="T et al. Fremanezumab for the preventive treatment of chronic" exact="migraine" post="N Engl J Med 2017 377 22 2113 2122"/>
 <result pre="license application for fremanezumab with priority review for prevention of" exact="migraine" post="and grants fast track designation for cluster headache development"/>
 <result pre="Goadsby PJ et al. Cost of healthcare for patients with" exact="migraine" post="in five European countries: results from the international burden"/>
 <result pre="in five European countries: results from the international burden of" exact="migraine" post="study (IBMS) J Headache Pain. 2012 13 5 361"/>
 <result pre="C Egeo G et al. Establishment of an Italian chronic" exact="migraine" post="database: a multicenter pilot study Neurol Sci 2018 39"/>
 <result pre="as predictors of efficacy of onabotulinumtoxin type a in chronic" exact="migraine" post="Headache. 2014 54 6 987 995 10.1111/head.12372 24673487 87."/>
 <result pre="87. Martelletti P The application of CGRP(r) monoclonal antibodies in" exact="migraine" post="spectrum: needs and priorities BioDrugs. 2017 31 6 483"/>
</results>
